The Liver for the Nonhepatologist Michael R. Charlton, MBBS Director of Hepatology and Liver Transplantation Intermountain Medical Center Salt Lake City, Utah
Chicago, Illinois: September 16, 2016
Learning Objectives After attending this presentation, participants will be able to: Choose optimal antiviral therapy for difficult-to-treat
patients, such as patients with end-stage renal disease and advanced liver disease. Evaluate and manage routine aspects of medical care related to liver disease in patients with chronic hepatitis C virus (HCV) infection, including determining severity of liver disease and screening for hepatocellular carcinoma.
Slide 1 of 58
Slide 2 of 58
Overview
• What is the natural history and prognosis of cirrhosis?
• How do you diagnose cirrhosis? • Managing common complications • Other Issues - immunization, medications, etc. in patients with cirrhosis
1
Slide 3 of 58
Overview
• What is the natural history and prognosis of cirrhosis?
• How do you diagnose cirrhosis? • Managing common complications • Other Issues - immunization, medications, etc. in patients with cirrhosis
Slide 4 of 58
Natural history and disease progression following HCV infection HCV infection Acute infection, 20–30% with symptoms Clearance of HCV RNA, 15–25%
Fulminant hepatitis, rare
Chronic infection, 75–85% Extrahepatic manifestations Variceal hemorrhage Ascites Encephalopathy Jaundice HCC
Chronic active hepatitis Cirrhosis, ~30% over 20 years
Decompensated cirrhosis, 5-year survival rate of 50%
Clinical burden HCC 1–4% per year HCC: hepatocellular carcinoma
Chen S, et al. Int J Med Sci 2006;3:47–52
Chronic HCV Infection Reduces Life Expectancy
Slide 5 of 58
25% died prematurely 64% died prematurely
Perspectives in Virology, August 2015
94% died prematurely
Pinchoff J, et al. Clin Infect Dis 2014;58:1047–54
2
Extrahepatic manifestations of HCV
Slide 6 of 58
• Mixed cryoglobulinemia (type II and III) Prevalence of HCV 80-90%; reverse 30-50% Glomerulonephritis- MPGN
• Porphyria cutanea tarda • Lymphoma (B cell) HCV present in 9-32%
• Type II DM OR 3.77 (1.8-7.9)
• Lichen Planus • Vitiligo • CNS Subhash C. Ann Intern Med, 1995. Zuckerman E. Ann Intern Med, 1997. Mehta SH. Ann Intern Med, 2000. Harris N. NEJM, 2002.
Slide 7 of 58
HCV eradication (SVR) is associated with a reduction in All-Cause Mortality
All-cause mortality (%)
Long-term follow-up study from 5 tertiary care hospitals of HCV patients with advanced fibrosis/cirrhosis (n=530)
Without SVR
P